-+ 0.00%
-+ 0.00%
-+ 0.00%

LUCID CAPITAL MARKETS Initiates Coverage On Opus Genetics with Buy Rating, Announces Price Target of $5

Benzinga·06/17/2025 15:27:30
Listen to the news
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating and announces Price Target of $5.